The Forefront of Innovation

About Us is on a mission to empower and connect researchers worldwide.

By enabling scientists to easily Outsource Everything but the Genius®, we are pioneering a faster, leaner and more innovation-centric approach to research. Our vision is to create a world in which scientists are limited only by their imagination.

Our partners include large and small pharmaceutical and biotechnology companies, crop science companies, cosmetic companies, Contract Research Organizations (CROs), government research institutes, university core facilities, academic researchers and citizen scientists.

Leadership Team

Laura Benitez, PhD
Sr. Director Customer Success

Laura was born in the UK and now lives with her family in Spain. She found her love for science while studying microbiology and immunology at university. Once her studies were complete, Laura worked for several pharmaceutical companies based in the UK and Spain in a Business Development role before joining in 2017, where she works closely with scientific, operations and procurement users to help them maximize their use of the platform, support their projects through to completion and to streamline scientific sourcing.

Brian Bonnell
Sr. VP Strategic Partnerships & Enterprise

Since joining in 2015, Brian has worked to build strong, collaborative relationships with key clients and partners to help ensure the continued success and growth of the platform.  Prior to joining, Brian held a variety of roles spanning engineering, manufacturing, procurement and finance in biotech and global pharmaceutical organizations including Merck & Co., Human Genome Sciences (GSK) and AstraZeneca.  He holds degrees in Chemical Engineering, Corporate Finance and Supply Chain Management from Penn State.

Tom Dexter
VP Global Business Development

Tom joined in 2017, bringing with him 20 years of experience leading global procurement teams at Rolls-Royce and AstraZeneca, where he led the strategic development and successful implementation of the marketplace across the global business. Having developed and delivered strategic innovation initiatives within procurement, he now helps new clients re-define and successfully implement their R&D outsourcing strategy through Tom holds a MSc in Global Supply Chain Management from Southampton University.

Adam Long
VP Strategic Partnerships & Enterprise

Adam has spent 14 years working in procurement, and the last seven years working within the pharmaceutical and biotech industry supporting programs in antibiotics, vaccine development and oncology research.  He has deep experience in indirect category management, procurement strategy & operations and clinical outsourcing. Adam holds an MBA from Indiana University’s Kelley School of Business and has completed a post-MBA leadership program at Harvard Business School.   At, he works on strategic partnerships and helping client’s realize value from their private marketplaces.

Sarah Harkcom
General Counsel, Legal

Sarah qualified as a lawyer in the UK in 1999. Prior to joining in 2017, she was Senior Legal Counsel for global R&D and pharmaceutical development operations at AstraZeneca. Sarah developed and built’s legal framework and contractual documentation, which enables close to 4,000 registered suppliers easily connect with over 25,000 signed researchers. As the company’s sole in-house lawyer, she negotiates and drafts agreements and provides legal advice to to help onboard clients and suppliers, develop the platform and business and oversee acquisitions.

Mark Herbert
Chief Business Officer

Mark has 20+ years’ experience in pharmaceutical and biotech research across multiple platforms and therapeutic areas. He last served as Interim President of Arcturus Therapeutics. Previously, he was Head of U.S. Business Development at WuXi AppTec. Mark previously served as Director of Pharmaceutical Sciences at Aragon Pharmaceuticals, Inc. which was acquired by Johnson & Johnson in 2013. He is an author or inventor on over 35 peer-reviewed manuscripts and patents and has led or contributed to the submission of 13 investigational new drug (IND) applications and one new drug application (NDA).

Daniel Kagan, PhD
President and COO

Dan is a bioengineer who has worked extensively with life science start-up companies. Prior to joining, he advised startups at eBoost Consulting, started a company called ChemoTactics and was the CTO of the UC-San Diego 100K Entrepreneur Challenge. In 2012, Dan was selected as a Siebel Scholar. Dan received an M.S. and Ph.D in Bioengineering from Joseph Wang’s lab at UCSD, where he was a Gordon Scholar. He received a B.S. degree, summa cum laude, from Rutgers in 2006.

Kristopher R Kagan
Sr. Vice President of Finance

Kristopher R Kagan is Sr. VP of Finance at, where he manages the Finance, Accounting and Human Resources departments and oversees the issuance of all company financial information, including statements, metrics and benchmarks, reporting and analysis and projections and forecasting. Before joining, he worked in corporate finance, where he has over 10 years of experience. Kris received his degree in Finance and Political Science from American University.

Kevin Lustig, PhD
CEO and Founder

Kevin is a scientist-entrepreneur with 30 years of research experience in academia and pharma. He co-founded in 2007. In 2001, he co-founded Kalypsys, a small pharmaceutical company. He was Director of Lead Discovery at Tularik from 1997-2001. He carried out postdoctoral work at Harvard Medical School after receiving a PhD degree from Marc Kirschner’s laboratory at UC-San Francisco and an A.B. degree, magna cum laude, from Cornell University.

Matt McLoughlin
Sr. Vice President of Compliance & Categories

Matt has 20+ years’ experience in the pharmaceutical industry working in both a scientific and commercial capacity.  Prior to joining, Matt worked within R&D Genetics and Personalised Healthcare for AstraZeneca before transferring into the R&D procurement organization, where he was responsible for pre-clinical and human biological sample categories.  Since joining in 2016, Matt has led our Compliance and Category departments, heading the cross industry team that developed of our award winning COMPLi® platform transforming compliance within the pharmaceutical industry.

Diana Ourthiague, PhD
Sr. Vice President of Accounts

Diana Ourthiague, PhD, is a biochemist and SVP of Customer Success at, where she oversees a global team that manages marketplace operations and customer service across the platform.  Since joining the company in 2014, she has worked closely with biopharma researchers to understand the challenges in identifying and outsourcing research to external partners. She is committed to delivering systems and processes that allow to emphasize the user experience and top-notch customer service. Diana received an M.S. and PhD in Biochemistry from the Signaling Systems Lab at UCSD (now at UCLA).

Patti Peeples, RPh, PhD
President of HealthEconomics.Com – a Company; VP of Evidence and Content

Patti is a health economist, pharmacist and Founder and President of HealthEconomics.Com, a Connected Community™ of healthcare value, evidence and market access stakeholders. Peeples also serves as VP of Evidence and Content at Widely published, Dr. Peeples serves on multiple scientific journal editorial boards and Board of Grants for AFPE. Patti holds a PhD in Health Economics from the University of the Sciences in Philadelphia and she completed a Clinical Pharmacy Residency at the Medical University of South Carolina.

Christopher Petersen
CTO and Founder

Chris is a software engineer who has worked extensively with drug researchers to develop online solutions to complex scientific processes. He co-founded in 2007. From 2002-2006 he was Director of Software Development at Kalypsys, a small pharmaceutical company. He was Director of Engineering at Learning Framework from 1999-2001. In 2018, Chris received the Cox Business Exemplary Award as part of the San Diego Top Tech Awards. Chris received a B.S. degree in Computer Science from Worcester Polytechnic Institute, where he received the Provost’s award.

Christoph Schittny
VP Strategic Partnerships & Enterprise

With 15+ years of extensive experience in the research and healthcare industry, Christoph is working towards making procurement and its processes one globally aligned ecosystem. His ambition is to create, construct and craft win-win(-win) results for all parties involved. As a lawyer, international procurement expert and innovation coach, he is convinced that is the one platform that will combine sourcing strategies, procurement processes and compliance workflows in one user friendly, efficient and effective digital innovation and sourcing marketplace.

Sherman Tang
VP Professional Services

Sherman leads’s Professional Services which bridges the gap between scientific/procurement professionals and technology experts. The department specializes in integrating systems and processes to optimize marketplace use and adoption. Since joining in 2009, he has contributed to the construction, expansion, and implementation of’s online research marketplaces. Sherman received a B.S. degree in Biochemistry and Cell Biology from the University of California, San Diego (UCSD).

Board Of Directors


Parker Hinshaw

Bootstrap Ventures

Parker Hinshaw was previously the CEO/founder of maxIT Healthcare, a consulting services company that was sold in 2015 for $500M+. He is now senior vice president of business development for MD Revolution. A successful leader over his 35-year career, Parker now sits on the boards and advises multiple innovative organizations and start-ups. Parker received a Bachelor of Business Administration (BBA) from Indiana University.


Andrew B. Martin, PhD

Informatics Specialist, Stanford University School of Medicine

Andy is an informatics expert specializing in the organization, analysis and visualization of big data. He co-founded in 2007. Currently, he builds tools to securely store clinical patient data at Stanford University. From 1999-2006, he was head of informatics at Kalypsys, a small pharmaceutical company. He received a PhD degree in Chemistry from Peter Schultz’s laboratory at the UC-Berkeley and a B.A. degree magna cum laude from Carleton College.

Jared A. Kesselheim

Jared A. Kesselheim, MD

Managing Partner, Leerink Transformation Partners

Co-founder and Managing Partner of Leerink Transformation Partners and co-leader of the firm’s growth equity investing in healthcare information technology and services. Prior to forming LTP in 2016, Jared was a Partner and the leader of the healthcare investing practice at Bain Capital Ventures. Jared also completed a residency in Internal Medicine at Massachusetts General Hospital.

ANDREW SCHWAB_BW_square 500x500

Andrew J. Schwab

Managing Partner, 5AM Ventures

Andrew J. Schwab is a Founder and Managing Partner of 5AM Ventures. Prior to founding 5AM in 2002, Andy was a Principal at Bay City Capital where he was involved with companies such as Cubist, PTC Therapeutics, Symyx and Syrrx. Previously Andy was VP of Business Development at Digital Gene Technologies and a VP in the life science investment banking group of Montgomery Securities. At 5AM, he has led the firm’s investments in and served on the Boards of numerous companies, many of which were acquired. Mr. Schwab also serves on the Boards of Trustees of the California Academy of Sciences, Davidson College and the National Venture Capital Association (NVCA). Mr. Schwab received a B.S. with Honors in Genetics & Ethics from Davidson College.


Kevin Lustig, PhD

CEO and Founder,

Kevin is a scientist-entrepreneur with 30 years of research experience in academia and pharma. He co-founded in 2007. In 2001, he co-founded Kalypsys, a small pharmaceutical company. He was Director of Lead Discovery at Tularik from 1997-2001. He carried out postdoctoral work at Harvard Medical School after receiving a PhD degree from Marc Kirschner’s laboratory at UC-San Francisco and an A.B. degree, magna cum laude, from Cornell University.

Scientific Advisory Board


Ted J. Torphy, PhD

Chief Science Officer, BioMotiv

With more than 30 years of experience in pharmaceutical R&D, Ted has been instrumental in the discovery and development of multiple marketed products. Since 2004 he has chaired the board of The Cystic Fibrosis Foundation Therapeutics, Inc. Ted currently serves as CSO of BioMotiv. Prior to that, Ted spent 12 years with Johnson & Johnson in high ranking managerial positions. Before Johnson & Johnson, Ted spent 17 years with SmithKline Beecham in various VP tier roles. He holds a B.S. degree in Pharmacy from the University of Wisconsin and a Ph.D. in Pharmacology and Toxicology from West Virginia University.


Randall W. King, MD PhD

Professor, Harvard Medical School

Randall is a Professor in the Department of Cell Biology at Harvard Medical School. Prior to joining the faculty at Harvard Medical School, Dr. King was a fellow at the Institute of Chemistry and Cell Biology at Harvard, where he developed new approaches in chemical genetics. Dr.King co-founded the drug discovery company Kalypsys in 2001, and served on its science advisory board for four years. He received an MD from Harvard Medical School after receiving a PhD from Mark Kirschner’s laboratory at the University of California, San Francisco. He received a B.A. degree in chemistry from Carleton College.


Julie A. Theriot, PhD

Professor, Stanford University

Julie is a Professor at the Stanford University School of Medicine, with appointments in the Department of Biochemistry and the Department of Microbiology & Immunology. Her group has developed computational, analytical and statistical methods for large-scale quantitative image and motion analysis. She has numerous awards for both research and teaching, including a MacArthur Foundation fellowship in 2004. Prior to 1997, Dr. Theriot was a Whitehead Fellow at the Whitehead Institute for Biomedical Research. She received a PhD in Cell Biology from the University of California at San Francisco in 1993, and BS degrees in Biology and Physics from MIT in 1988.


Bruce Conklin, MD

Sr Investigator Gladstone Inst. and Professor UCSF

Bruce is a Senior Investigator at the Gladstone Institute and a Professor at the University of California, San Francisco. Dr. Conklin received an A.B. degree in public health from UC Berkeley in 1982. He completed an MD degree at Case Western Reserve University in Cleveland in 1988. From 1995 to 2001, Dr. Conklin was the Associate Director of the General Clinical Research Center at San Francisco General Hospital. Dr. Conklin was the co-chair of the UCSF public science project in 1994, and is co-chair of the UCSF-California Academy of Sciences Affiliation Task Force.

Jeffrey Hager, PHD

Jeffrey Hager, PHD

Co-Founder, Senior Vice President and Head of Biology, IDEAYA Biosciences

Since November 2015, Jeff has served as co-founder and Senior Vice President and Head of Biology at IDEAYA Biosciences. Prior to IDEAYA, he was VP of Biology at Seragon Pharmaceuticals, which was acquired by Roche/Genentech for up to $1.7 billion. Previously, Jeff was Senior Director at Aragon Pharmaceuticals, which was acquired by Johnson & Johnson for up to $1 billion. Prior to Aragon, he was Associate Director of Biology at Apoptos, Inc. and Head of Cancer Pharmacology at Kalypsys, Inc. He did graduate studies at both Princeton and University of California at Berkeley, the latter from which he received a PhD in molecular and cell biology.  He was also a postdoctoral fellow and staff scientist at the University of California at San Francisco.

Andrew Hessel

Andrew Hessel, PHD

President, Humane Genomics Inc.

Andrew Hessel is the president of Humane Genomics, an early stage company developing synthetic viruses for animal and human health. He is also the co-founder and chairman of the Center of Excellence for Engineering Biology and the Genome Project-write, the international scientific effort to engineer large genomes, including the human genome.

Andrew Shiau, PHD

Andrew Shiau, PHD

Small Molecule Discovery Program Director, Ludwig Institute (San Diego Branch)

Andrew is Director of the Small Molecule Discovery Program at the San Diego branch of the Ludwig Institute where he leads a highly collaborative, systematic effort to use chemical biology to translate the cutting-edge research of Ludwig scientists into new cancer medicines. Before joining Ludwig in 2009, he was Director of Biology at Kalypsys, Inc. Before that, Andrew was head of the Orphan Nuclear Receptor Program at Tularik.  He received his PhD in biochemistry and biophysics from the University of California, San Francisco.

Michael Jackson, PHD

Michael Jackson, PHD

Senior Vice President of Drug Discovery and Development, Sanford Burnham Prebys Medical Discovery Institute

Michael is Senior Vice President of Drug Discovery and Development at Sanford Burnham Prebys Medical Discovery Institute. He works closely with SBP’s senior leadership to seek new avenues of support for preclinical and clinical drug development initiatives to enable the overall mission of the Institute to translate basic research to new products. Prior to this, Michael was Chief Scientific Officer at Johnson & Johnson. He received his PhD in molecular biology/ toxicology from the University of Dundee in Scotland.

Bernard Munos

Bernard Munos, PhD

Founder, InnoThink Center for Research in Biomedical Innovation

Bernard H. Munos is the founder of the InnoThink Center for Research in Biomedical Innovation, a consultancy that focuses on pharmaceutical innovation — specifically, where it comes from and how to get more of it. He previously served as an advisor for corporate strategy at Eli Lilly and Company, where he focused on disruptive innovation and the radical redesign of research and development. His work has been published in Nature and Science, and was recently profiled by Forbes magazine. In 2014, the popular industry publication FiercePharma named him one of the 25 most influential people in biopharma. Munos received his MBA from Stanford University and holds graduate degrees in agricultural economics and animal science from the University of California, Davis, and the Paris Institute of Technology for Life, Food and Environmental Sciences. He is a Director of Phoenix Nest, a foundation dedicated to finding treatments for Sanfilippo syndrome, and serves on the Advisory Council and the Cures Acceleration Network Review Board of NIH’s National Center for Advancing Translational Sciences (NCATS). He is also a non-executive Director for Glenmark Pharmaceuticals, and advises companies, government-funded research organizations, and disease foundations on how to become better innovators.